These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21547266)

  • 1. Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas.
    Fozza C; Longinotti M
    Adv Hematol; 2011; 2011():960137. PubMed ID: 21547266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Accompanying hemolysis in lymphoproliferative diseases].
    Banihashemi A; Heinz R
    Acta Med Austriaca; 1979; 6(5):183-6. PubMed ID: 555212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
    Mauro FR; Foa R; Cerretti R; Giannarelli D; Coluzzi S; Mandelli F; Girelli G
    Blood; 2000 May; 95(9):2786-92. PubMed ID: 10779422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia.
    Paganelli M; Patey N; Bass LM; Alvarez F
    Pediatrics; 2014 Oct; 134(4):e1206-10. PubMed ID: 25201797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
    Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
    Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
    Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
    Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
    Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
    Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for chronic lymphocytic leukemia.
    Robak T
    Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
    Di Raimondo F; Giustolisi R; Cacciola E; O'Brien S; Kantarjian H; Robertson LB; Keating MJ
    Leuk Lymphoma; 1993 Sep; 11(1-2):63-8. PubMed ID: 8220155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
    Engelhard M
    Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Cvetković RS; Perry CM
    BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.
    D'arena G; Grandone E; Di Minno MN; Musto P; Di Minno G
    Blood Transfus; 2016 May; 14(2):255-61. PubMed ID: 26509821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Lang D; George C
    JBI Libr Syst Rev; 2011; 9(1):1-30. PubMed ID: 27819968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
    Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
    Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic lymphocytic leukemia].
    Maurer C; Hallek M
    Dtsch Med Wochenschr; 2013 Oct; 138(42):2153-66. PubMed ID: 24104591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.